Table of Contents Show
India’s battle against cancer is intensifying. With millions of new diagnoses recorded each year and treatment costs continuing to rise, the need for scalable, affordable oncology solutions has never been more urgent. Against this backdrop, Oncare – a startup redefining how cancer care is delivered in India has taken a significant step forward by securing Rs 27 crore in Series A funding.
A Vote of Confidence from Marquee Investors
The funding round was led by Sky Impact Capital, a firm with a strategic focus on building specialised healthcare networks across the country. Joining the round were Huddle Ventures, Lotus Herbal Group, SteerX, and Tremis Capital – a diverse group of backers whose participation reflects broad confidence in Oncare’s vision. This Series A follows the company’s earlier seed raise of $1 million, also anchored by Huddle Ventures, marking a clear progression in investor trust and organisational maturity.
A Model Built for Scale
What distinguishes Oncare from conventional oncology providers is its asset light, partnership driven approach. Rather than investing heavily in proprietary hospital infrastructure, the company collaborates with accredited healthcare facilities to deliver a comprehensive suite of oncology services spanning medical, surgical, and radiation oncology. Alongside clinical care, Oncare manages insurance coordination, quality oversight, and transparent pricing, creating a patient centric experience that has historically been absent in the mid market segment.
Since its founding in 2023, the company has established multiple operational centres across the Delhi-NCR region, building a credible early stage presence in one of India’s most competitive healthcare markets.
Also Read: Biotech Firm Pandorum Technologies Closes $18 Million Series B Round Led by Protons Corporate
Expanding the Reach of Quality Care
The fresh capital will be channelled into two strategic priorities. First, Oncare intends to extend its footprint beyond metro cities into tier II and tier III markets – regions where cancer care infrastructure remains critically underdeveloped. Second, the company will invest in technology platforms designed to streamline clinical workflows, strengthen care coordination, and elevate the overall patient journey.
Tapping Into a High Growth Market
India’s cancer treatment industry is projected to reach Rs 43,000 crore by FY28, expanding at an annual rate of approximately 14%. Yet access to quality care continues to be unevenly distributed. Oncare’s model addresses this structural gap directly making it not only a compelling business proposition but also a meaningful contributor to public health outcomes.
As the startup scales nationally, it stands positioned to reshape the oncology landscape in a country where timely, affordable cancer care can quite literally save lives.
